D. G. Tang

This study evaluates folate-conjugated miR-34a as a potential prostate cancer therapeutic, finding limited efficacy due to low FOLR1 expression in prostate cancer cells.

The paper identifies heterogeneous subpopulations of slow-cycling cells in TNBC and shows AP-1, particularly the JunB subunit, regulates dormancy and drug resistance.

The paper uses multi-omics single-cell data to define the epigenetic basis of castration-resistant prostate luminal cells in mice and identifies key molecular pathways involved.

The paper identifies intron retention as a hallmark of aggressive prostate cancer and highlights the spliceosome as a therapeutic target by analyzing splicing dysregulation across prostate cancer progression.